Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Liabilities and Shareholders Equity of $58.6 million for Q1 2026, up 116.35% year-over-year from $27.1 million in Q1 2025, and up 95.71% quarter-over-quarter from $29.9 million in Q4 2025.

Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $58.6 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 116.35% year-over-year to $58.6 million; the TTM figure through Mar 2026 stood at $162.4 million (up 9.79% YoY), while the FY2025 annual figure was $29.9 million, down 16.54% from the prior year.
  • Liabilities and Shareholders Equity rose to $58.6 million in Q1 2026 per SLGL's latest filing, from $29.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $58.6 million in Q1 2026 and bottomed at $27.1 million in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $44.6 million across 5 years, with a median of $45.3 million in 2023.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 32.61% — and 2026, when it jumped 116.35%.
  • Sol-Gel Technologies' Liabilities and Shareholders Equity stood at $46.6 million in 2022, then decreased by 2.88% to $45.3 million in 2023, then declined by 20.85% to $35.8 million in 2024, then retreated by 16.54% to $29.9 million in 2025, then jumped by 95.71% to $58.6 million in 2026.
  • Business Quant data shows SLGL's Liabilities and Shareholders Equity at $58.6 million in Q1 2026, $29.9 million in Q4 2025, and $34.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Sol-Gel Technologies 240.26 Mn 230.12 Mn - 58.55 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 58.55 Mn
Dec 31, 2025 29.92 Mn
Sep 30, 2025 34.59 Mn
Jun 30, 2025 39.31 Mn
Mar 31, 2025 27.06 Mn
Dec 31, 2024 35.85 Mn
Sep 30, 2024 42.98 Mn
Jun 30, 2024 42.01 Mn
Mar 31, 2024 39.91 Mn
Dec 31, 2023 45.29 Mn
Sep 30, 2023 49.86 Mn
Jun 30, 2023 55.10 Mn
Mar 31, 2023 49.04 Mn
Dec 31, 2022 46.63 Mn
Sep 30, 2022 51.29 Mn
Jun 30, 2022 54.98 Mn
Mar 31, 2022 56.06 Mn
Dec 31, 2021 69.19 Mn
Sep 30, 2021 52.83 Mn
Jun 30, 2021 46.41 Mn